低级别CEAP临床分级患者接受氰基丙烯酸酯胶粘合与腔内激光消融后的症状改善
本研究回顾性纳入2018至2019年325条肢体(279例C0-C3 EpAsPr患者,其中66.1%为C0-C1),比较氰基丙烯酸酯消融(CA)联合超声引导泡沫硬化疗法(UGFS)与腔内激光消融(EVLA)联合UGFS的症状改善。倾向性评分匹配后174条肢体(每组87条)分析显示,夜间抽筋(94.7%)和瘙痒(93.8%)改善最明显,CA组手术时间更短且围术期疼痛评分更低。两组术后3个月症状严重度、VCSS、CIVIQ-14及满意度改善相当。
要点
- 低级别CEAP患者CA+UGFS与EVLA+UGFS均显著改善症状,夜间抽筋和瘙痒改善率最高。
- CA+UGFS较EVLA+UGFS手术时间更短、围术期疼痛评分更低。
- 两组术后3个月症状、VCSS、CIVIQ-14及满意度改善无显著差异。
核心结论
- CA和EVLA联合UGFS的微创腔内手术可为低级别CEAP患者提供显著的症状改善。
研究设计与样本
- 回顾性倾向性评分匹配分析,数据来自前瞻性设计的病例报告表。
- 2018至2019年纳入279例C0-C3 EpAsPr患者的325条肢体,其中66.1%为C0-C1。
- 匹配后174条肢体(CA+UGFS组87条,EVLA+UGFS组87条)纳入分析。
主要发现
- 症状改善率:夜间抽筋94.7%、瘙痒93.8%、沉重感85.2%、麻木77.8%、疼痛60.9%。
- CA+UGFS组手术时间20.1±10.6分钟,短于EVLA+UGFS组的28.4±10.9分钟(P=.001)。
- CA+UGFS组围术期疼痛视觉模拟评分2.99±2.34,低于EVLA+UGFS组的3.74±2.49(P=.03)。
- 两组术后3个月症状严重度评分、VCSS、CIVIQ-14评分及满意度评分改善相当(P值范围.085至1.0)。
- CA组发生2例腔内胶诱导血栓形成和24例(27.6%)IV型超敏反应。
临床怎么用
- 对于低级别CEAP临床分级的原发性浅静脉反流患者,可考虑CA+UGFS或EVLA+UGFS以改善症状。
- CA+UGFS可能缩短手术时间并减轻围术期疼痛,但需注意IV型超敏反应和腔内胶诱导血栓形成风险。
局限性
- 回顾性研究设计,尽管采用倾向性评分匹配,仍可能存在未测量混杂。
- 术后数据仅分析至3个月,缺乏长期随访结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Low-grade primary superficial venous reflux (C0-C3 EpAsPr [Ep (primary), As (superficial), and Pr (reflux)]) is a common feature of chronic venous disease. However, the procedural efficacy focusing on symptom characteristics and improvement patterns in this population has not been fully explored. METHODS: From 2018 to 2019, 325 limbs from 279 patients with C0-C3 EpAsPr (including 66.1% with C0-C1) who had undergone cyanoacrylate ablation (CA) with ultrasound-guided foam sclerotherapy (UGFS) or endovenous laser ablation (EVLA) with UGFS were included in the present study. Venous symptoms were classified into five categories: leg heaviness, calf cramping, itching sensation, pain, and numbness. A retrospective propensity score-matched analysis of data collected using a prospectively designed case report form was performed to identify the improvement magnitude of each symptom. As secondary outcomes, the postoperative changes in symptom severity (0-5 points), venous reflux-originated severity score, venous clinical severity score (VCSS), and 14-item chronic venous insufficiency quality of life questionnaire (CIVIQ-14) were evaluated in a 3-month postoperative data analysis. RESULTS: After adjusting the data, 174 limbs (CA with UGFS, n = 87; EVLA with UGFS, n = 87) were matched. The symptoms with the greatest improvement after treatment were night cramping (94.7%) and itching (93.8%), followed by heaviness (85.2%), numbness (77.8%), and pain (60.9%). All symptom improvement scores after each endovenous procedure showed similar patterns in both groups. The advantages of CA with UGFS over EVLA with UGFS were a shorter procedure time (20.1 ± 10.6 minutes vs 28.4 ± 10.9 minutes; P = .001) and lower perioperative visual analog for pain scores (2.99 ± 2.34 vs 3.74 ± 2.49; P = .03). Compared with the preoperative values, the venous reflux originated severity score, VCSS, CIVIQ-14 score, and symptom severity score were significantly improved in both groups (P < .001 for all). Improvements in all five symptoms (P = .085 to P = 1.0), VCSS (P = .435), CIVIQ-14 score (P = .788), and satisfaction score (P = .392) at 3 months postoperatively were comparable between the two groups. In the CA group, 2 cases of endovenous glue-induced thrombosis and 24 cases (27.6%) of type IV hypersensitivity reactions occurred. CONCLUSIONS: Minimally invasive endovenous surgery with CA and EVLA provides significant symptom improvement for patients with low-grade CEAP classes.
引用
- Yie K. Symptom improvement after cyanoacrylate glue adhesion and endovenous laser ablation in low-grade CEAP clinical classes. J Vasc Surg Venous Lymphat Disord. 2021. PMID: 34271248. doi:10.1016/j.jvsv.2021.07.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。